Edition:
India

Evolus Inc (EOLS.OQ)

EOLS.OQ on NASDAQ Stock Exchange Global Market

12.50USD
6 Dec 2019
Change (% chg)

$-0.00 (-0.04%)
Prev Close
$12.51
Open
$12.52
Day's High
$12.71
Day's Low
$12.33
Volume
97,572
Avg. Vol
126,255
52-wk High
$30.25
52-wk Low
$10.29

Latest Key Developments (Source: Significant Developments)

Tang Capital Partners Reports 5.8% Passive Stake In Evolus As Of November 7 - SEC Filing
Tuesday, 19 Nov 2019 

Nov 18 (Reuters) - Evolus Inc ::TANG CAPITAL PARTNERS LP REPORTS 5.8% PASSIVE STAKE IN EVOLUS INC AS OF NOVEMBER 7 - SEC FILING.  Full Article

Evolus Inc Announces Proposed Public Offering Of Common Stock
Thursday, 7 Nov 2019 

Nov 6 (Reuters) - Evolus Inc ::EVOLUS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.EVOLUS INC SAYS INTENDS TO USE NET PROCEEDS OF OFFERING TO CONTINUE TO FUND COMMERCIALIZATION OF JEUVEAU.  Full Article

Evolus Receives Approval For Nuceiva In European Union
Tuesday, 1 Oct 2019 

Oct 1 (Reuters) - Evolus Inc ::EVOLUS RECEIVES APPROVAL FOR NUCEIVA™ IN THE EUROPEAN UNION.EVOLUS INC - EXPECTS NUCEIVA™ TO LAUNCH IN EUROPE IN 2020.EVOLUS INC - COMPANY EXPECTS TO LAUNCH NUCEIVA™ IN CANADA IN Q4 THROUGH ITS PARTNER CLARION.  Full Article

Evolus Says Gross Margins May Fluctuate In The Future Due To Various Marketing Programs
Monday, 12 Aug 2019 

Aug 12 (Reuters) - Evolus Inc ::EVOLUS INC - GENERATED $2.3 MILLION IN JEUVEAU NET REVENUE IN Q2 2019.EVOLUS INC - QTRLY LOSS PER SHARE $1.37.EVOLUS INC - QTRLY NON-GAAP LOSS FROM OPERATIONS WAS $31.3 MILLION VERSUS $5.3 MILLION.EVOLUS INC - TOTAL CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS WERE $99.9 MILLION AS OF JUNE 30.EVOLUS INC - GROSS MARGIN MAY FLUCTUATE IN THE FUTURE DUE TO VARIOUS MARKETING PROGRAMS.  Full Article

Evolus Q3 Loss Per Share $0.48
Tuesday, 6 Nov 2018 

Nov 5 (Reuters) - Evolus Inc ::EVOLUS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.48.Q3 EARNINGS PER SHARE VIEW $-0.39 -- THOMSON REUTERS I/B/E/S.GRANTED MARKETING APPROVAL FOR DWP-450 BY HEALTH CANADA.REMAIN ON TRACK FOR ANTICIPATED U.S. COMMERCIAL LAUNCH OF DWP-450 IN SPRING 2019.TOTAL CASH WAS $105.2 MILLION AS OF SEPTEMBER 30, 2018, AN INCREASE OF $61.6 MILLION COMPARED TO JUNE 30, 2018.  Full Article

Evolus Granted Approval Of DWP-450 By Health Canada
Friday, 17 Aug 2018 

Aug 17 (Reuters) - Evolus Inc ::EVOLUS GRANTED APPROVAL OF DWP-450 BY HEALTH CANADA.EVOLUS - EXPECTS TO LAUNCH DWP-450 IN U.S. IN SPRING 2019, EXPECTS OPINION FROM COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE BY Q1 2019.EVOLUS INC - WILL MARKET DWP-450 IN CANADA THROUGH ITS PARTNER CLARION MEDICAL TECHNOLOGIES, INC.  Full Article

Evolus Prices Public Offering Of 4 Mln Common Shares At $20/Share
Thursday, 19 Jul 2018 

July 18 (Reuters) - Evolus Inc ::EVOLUS, INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 4.00 MILLION COMMON SHARES PRICED AT $20.00PER SHARE.  Full Article

Evolus Says Co Offering Five Million Common Shares
Tuesday, 17 Jul 2018 

July 16 (Reuters) - Evolus Inc ::EVOLUS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 5.00 MILLION COMMON SHARES.  Full Article

Evolus Reports Q4 Earnings Per Share $0.24
Thursday, 29 Mar 2018 

March 29 (Reuters) - Evolus Inc ::EVOLUS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 EARNINGS PER SHARE $0.24.EVOLUS- QTRLY NET INCOME PRIMARILY ATTRIBUTABLE TO FAVORABLE RE-MEASUREMENT OF DEFERRED TAX LIABILITY FROM DECREASE IN TAX RATES UNDER U.S. TAX ACT.  Full Article

Evolus Inc Shares Debut 6.3 Pct below IPO Price
Thursday, 8 Feb 2018 

Feb 8 (Reuters) - :EVOLUS INC SHARES OPEN AT $11.25 IN DEBUT ON THE NASDAQ VERSUS IPO PRICE OF $12 PER SHARE.  Full Article

UPDATE 1-Evolus reports sales of its Botox rival ahead of expectations

Aug 12 Medical aesthetics company Evolus Inc on Monday beat Wall Street estimates for second-quarter revenue from its newly launched rival to Allergan Plc's Botox, which has dominated the medical aesthetics market for more than a decade.